Cite
Symonds L, Jenkins I, Linden HM, et al. A Phase II Study Evaluating the Safety and Efficacy of Sunitinib Malate in Combination With Weekly Paclitaxel Followed by Doxorubicin and Daily Oral Cyclophosphamide Plus G-CSF as Neoadjuvant Chemotherapy for Locally Advanced or Inflammatory Breast Cancer. Clin Breast Cancer. 2021;22(1):32-42doi: 10.1016/j.clbc.2021.05.009.
Symonds, L., Jenkins, I., Linden, H. M., Kurland, B., Gralow, J. R., Gadi, V. V. K., Ellis, G. K., Wu, Q., Rodler, E., Chalasani, P., Chai, X., Riedel, J., Scca Network Investigators, Stopeck, A., Brown-Glaberman, U., & Specht, J. M. (2022). A Phase II Study Evaluating the Safety and Efficacy of Sunitinib Malate in Combination With Weekly Paclitaxel Followed by Doxorubicin and Daily Oral Cyclophosphamide Plus G-CSF as Neoadjuvant Chemotherapy for Locally Advanced or Inflammatory Breast Cancer. Clinical breast cancer, 22(1), 32-42. https://doi.org/10.1016/j.clbc.2021.05.009
Symonds, Lynn, et al. "A Phase II Study Evaluating the Safety and Efficacy of Sunitinib Malate in Combination With Weekly Paclitaxel Followed by Doxorubicin and Daily Oral Cyclophosphamide Plus G-CSF as Neoadjuvant Chemotherapy for Locally Advanced or Inflammatory Breast Cancer." Clinical breast cancer vol. 22,1 (2022): 32-42. doi: https://doi.org/10.1016/j.clbc.2021.05.009
Symonds L, Jenkins I, Linden HM, Kurland B, Gralow JR, Gadi VVK, Ellis GK, Wu Q, Rodler E, Chalasani P, Chai X, Riedel J, Scca Network Investigators, Stopeck A, Brown-Glaberman U, Specht JM. A Phase II Study Evaluating the Safety and Efficacy of Sunitinib Malate in Combination With Weekly Paclitaxel Followed by Doxorubicin and Daily Oral Cyclophosphamide Plus G-CSF as Neoadjuvant Chemotherapy for Locally Advanced or Inflammatory Breast Cancer. Clin Breast Cancer. 2022 Jan;22(1):32-42. doi: 10.1016/j.clbc.2021.05.009. Epub 2021 May 24. PMID: 34158245; PMCID: PMC8611115.
Copy
Download .nbib